Limitations of current Parkinson's disease therapy.
Identifieur interne : 000316 ( Ncbi/Curation ); précédent : 000315; suivant : 000317Limitations of current Parkinson's disease therapy.
Auteurs : Olivier Rascol ; Pierre Payoux ; Fabienne Ory ; Joaquim J. Ferreira ; Christine Brefel-Courbon ; Jean-Louis MontastrucSource :
- Annals of neurology [ 0364-5134 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (classification), Antiparkinson Agents (therapeutic use), Cognition Disorders (chemically induced), Drug Resistance, Dysarthria (chemically induced), Dyskinesia, Drug-Induced (etiology), Electric Stimulation Therapy (methods), Globus Pallidus (physiology), Globus Pallidus (surgery), Humans, Neurosurgical Procedures, Parkinson Disease (drug therapy), Parkinson Disease (surgery), Parkinson Disease (therapy), Psychoses, Substance-Induced (etiology), Quality of Life, Subthalamic Nucleus (physiology), Subthalamic Nucleus (surgery).
- MESH :
- chemical , adverse effects : Antiparkinson Agents.
- chemical , classification : Antiparkinson Agents.
- chemical , therapeutic use : Antiparkinson Agents.
- chemically induced : Cognition Disorders, Dysarthria.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- methods : Electric Stimulation Therapy.
- physiology : Globus Pallidus, Subthalamic Nucleus.
- surgery : Globus Pallidus, Parkinson Disease, Subthalamic Nucleus.
- therapy : Parkinson Disease.
- Drug Resistance, Humans, Neurosurgical Procedures, Quality of Life.
Abstract
Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the "honeymoon" period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from "dopa-resistant" motor symptoms (speech impairment, abnormal posture, gait and balance problems), "dopa-resistant" nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug-related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety.
DOI: 10.1002/ana.10513
PubMed: 12666094
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001131
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001090
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001090
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000316
Links to Exploration step
pubmed:12666094Curation
No country items
Olivier Rascol<affiliation><nlm:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France.</nlm:affiliation><wicri:noCountry code="subField">University Hospital France</wicri:noCountry></affiliation>Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Limitations of current Parkinson's disease therapy.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><nlm:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France.</nlm:affiliation><wicri:noCountry code="subField">University Hospital France</wicri:noCountry></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12666094</idno><idno type="pmid">12666094</idno><idno type="doi">10.1002/ana.10513</idno><idno type="wicri:Area/PubMed/Corpus">001131</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001131</idno><idno type="wicri:Area/PubMed/Curation">001090</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001090</idno><idno type="wicri:Area/PubMed/Checkpoint">001090</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001090</idno><idno type="wicri:Area/Ncbi/Merge">000316</idno><idno type="wicri:Area/Ncbi/Curation">000316</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Limitations of current Parkinson's disease therapy.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><nlm:affiliation>Clinical Investigation Centre and Department of Clinical Pharmacology, Toulouse, University Hospital France.</nlm:affiliation><wicri:noCountry code="subField">University Hospital France</wicri:noCountry></affiliation></author><author><name sortKey="Payoux, Pierre" sort="Payoux, Pierre" uniqKey="Payoux P" first="Pierre" last="Payoux">Pierre Payoux</name></author><author><name sortKey="Ory, Fabienne" sort="Ory, Fabienne" uniqKey="Ory F" first="Fabienne" last="Ory">Fabienne Ory</name></author><author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="ISSN">0364-5134</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (classification)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cognition Disorders (chemically induced)</term><term>Drug Resistance</term><term>Dysarthria (chemically induced)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Electric Stimulation Therapy (methods)</term><term>Globus Pallidus (physiology)</term><term>Globus Pallidus (surgery)</term><term>Humans</term><term>Neurosurgical Procedures</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (surgery)</term><term>Parkinson Disease (therapy)</term><term>Psychoses, Substance-Induced (etiology)</term><term>Quality of Life</term><term>Subthalamic Nucleus (physiology)</term><term>Subthalamic Nucleus (surgery)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Cognition Disorders</term><term>Dysarthria</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation Therapy</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Globus Pallidus</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term><term>Parkinson Disease</term><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance</term><term>Humans</term><term>Neurosurgical Procedures</term><term>Quality of Life</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa and other dopaminergic medications drastically improve the motor symptoms and quality of life of patients with Parkinson's disease in the early stages of the disease. However, once the "honeymoon" period has waned, usually after a few years of dopaminergic therapy, patients become progressively more disabled despite an ever more complex combination of available antiparkinsonian treatments. Sooner or later, they suffer from "dopa-resistant" motor symptoms (speech impairment, abnormal posture, gait and balance problems), "dopa-resistant" nonmotor signs (autonomic dysfunction, mood and cognitive impairment, sleep problems, pain) and/or drug-related side effects (especially psychosis, motor fluctuations, and dyskinesias). Therefore, the current antiparkinsonian therapy cannot be considered as ideal with regard to both efficacy and safety.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000316 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000316 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:12666094
|texte= Limitations of current Parkinson's disease therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:12666094" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |